Skip to content
IFPMA Twitter
IFPMA LinkedIn
IFPMA Youtube
IFPMA Slideshare
IFPMA Flickr
IFPMA RSS
Search for:
Primary Menu
Who We Are
IFPMA in Brief
Our Governance and Leadership
Our Membership
Full Members
Associations
Companies
Affiliate Members
Our Experts
Join Us
Topics
News Center
News Releases
Blog
Global Health Matters
Science Matters
DG’s Column
Statements
Resources
Publications
News Releases
Statements
Position Papers
Publications
External Studies
Infographics
Event Highlights
Multimedia
Interviews
Videos
Slides
IFPMA Interactive Platforms
IFPMA COVID-19 Hub
Global Health Progress
50 Years of Global Health Progress
Events
Upcoming IFPMA Events
Geneva Pharma Forums
Assemblies
Other IFPMA Events
IFPMA in External Events
IFPMA Press Briefings
Past IFPMA Events
Geneva Pharma Forums
Assemblies
Other IFPMA Events
IFPMA in External Events
IFPMA Press Briefings
Partners
BCR
Inventing Medicines and Vaccines
Strengthening Regulatory Systems
Ethics and Business Integrity
Boosting Innovation and Access
Tackling Global health challenges
Climate change
Economic footprint
IP
Sustainable innovation
Value of innovation
spotlight
Value of innovation
African Medicines Agency
Biosimilars
Biotherapeutic medicines
Falsified medicines
Import testing
Pharmacovigilance
Quality, safety, and efficacy
Regulatory conferences
Regulatory system strengthening / Harmonization
Supply chain
The Africa Regulatory Network (ARN)
The ARN: Le réseau africain de réglementation pharmaceutique
spotlight
Pharmacovigilance
IFPMA Code of Practice (2019)
Our Ethos in Action
Our Ethos
Code eLearning Tool
IFPMA Notes for Guidance
IFPMA Complaint Operating Procedure
How to File a Code Complaint
Complaint Submission Form
Cases
Business Ethics for APEC SMEs Initiative
Consensus Framework for Ethical Collaboration
spotlight
IFPMA Code of Practice (2019)
Access to medicines
Global Policy Principles on Digital Health
Health technology assessment
IP
Technology Transfer
Trade
spotlight
Access to medicines
Ageing
Antimicrobial resistance
Cancer
Child and maternal health
COVID-19
Diabetes
Ebola
Falsified medicines
HIV/AIDS
Influenza
Malaria
Mental and neurological disorders
Neglected tropical diseases
Non-communicable diseases
Pandemic Preparedness
Public health implications of the implementation of the Nagoya Protocol
Rare diseases
Supply chain
Sustainable development goals
Tuberculosis
Universal Health Coverage
Vaccination confidence
Vaccines innovation
Vaccines protect communities
Vaccines sustainability
Value of immunization
Viral hepatitis
spotlight
Universal Health Coverage
Home
>
Resources
>
Statements
Filters
Categories
Event Highlights
External Studies
Infographics
Interviews
News Releases
Photos
Podcasts
Position Papers
Publications
Related Links
Slides
Statements
Stories
Videos
Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Apply Filters
Reset
Statements
IFPMA, GSCF, DITTA, and GMTA Statement on NCDs for WHA75 agenda item 14.1
25 May 2022
IFPMA, GSCF, and DITTA Statement on Health Emergencies for WHA75 agenda item 16.2
24 May 2022
Open Letter on ACT-A Therapeutics and Ongoing Roadblocks to Enhancing Access
10 May 2022
IFPMA statement on Quad’s Outcome Document on TRIPS
10 May 2022
Introductory remarks by Thomas Cueni at IFPMA media briefing on 13 April 2022
13 April 2022
IFPMA statement at public hearings regarding a new international instrument on pandemic preparedness and response
13 April 2022
IFPMA comment on draft guidance on value of new antibiotics as part of UK “subscription-type”
12 April 2022
Joint Industry Statement on the War in Ukraine
21 March 2022
IFPMA statement on TRIPS discussion document
16 March 2022
Statement delivered at Panel Discussion on Universal Access to Vaccines - 20th meeting, 49th Regular
10 March 2022
Global Pandemic Preparedness Summit & CEPI Replenishment
08 March 2022
Pharmaceutical industry response to the crisis in Ukraine
02 March 2022
« Previous
1
2
3
4
…
20
Next »